Roche / Chugai Pharmaceutical : Vabysmo, the first bispecific antibody in ophthalmology for nAMD and DME, approved in Japan Montag, 28. März 2022 - 18:06
| Investor Update |  |
Dear Investor,
Please find attached a press release by Chugai:
https://www.roche.com/220328_IR_Chugai_Vabysmo.pdf
Do not hesitate to contact us for any further questions.
With best regards,
Roche Investor Relations |
|
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
|
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
|
|
|
Investor Relations North America |
|
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
|
All rights reserved ©2022 F. Hoffmann-La Roche Ltd.
Group Communications, Grenzacherstrasse 124, CH-4070 Basel, Switzerland